Literature DB >> 11313939

Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody.

B Liu1, M Fang, Y Lu, J Mendelsohn, Z Fan.   

Abstract

DiFi human colon carcinoma cells are stimulated by the transforming growth factor-alpha (TGF-alpha)/epidermal growth factor (EGF) receptor autocrine loop. Exposure of DiFi cells to monoclonal antibody (mAb) 225, which blocks ligand-induced activation of the EGF receptor, induces G1 arrest and subsequent cell death via apoptosis. We investigated the signal pathways by which basic fibroblast growth factor (bFGF) and insulin-like growth factor-1 (IGF-1) modulate mAb 225-induced G1 arrest and apoptosis in DiFi cells. Both bFGF and IGF-1 activated the mitogen-activated protein kinase (MAPK) kinase (MEK) pathway in DiFi cells. Additionally, IGF-1 activated the phosphoinositide 3-kinase (PI-3K)/Akt pathway. Both bFGF and IGF-1 inhibited mAb 225-induced apoptosis; however, bFGF provided sustained protection against apoptosis, while the protection by IGF-1 was only temporary. Also, bFGF reversed the mAb 225-induced increase in the p27(Kip1) level, inhibition of cyclin-dependent kinase-2 (CDK-2) activity, dephosphorylation of the retinoblastoma (Rb) protein and the resultant G1 arrest of the cells. In contrast, IGF-1 did not reverse such effects by mAb 225. The prevention of mAb 225-induced G1 arrest and apoptosis in DiFi cells by bFGF was sensitive to the MEK/MAPK inhibitor PD98059 but not to the PI-3K inhibitor LY294002. In contrast, inhibition of apoptosis by IGF-1 in DiFi cells was sensitive only to LY294002 and not to PD98059. These results further our understanding of how mAb 225 induces apoptosis in DiFi cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11313939     DOI: 10.1038/sj.onc.1204277

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  30 in total

1.  Roles of autophagy in cetuximab-mediated cancer therapy against EGFR.

Authors:  Xinqun Li; Yang Lu; Tianhong Pan; Zhen Fan
Journal:  Autophagy       Date:  2010-11       Impact factor: 16.016

Review 2.  Genomic diversity of colorectal cancer: Changing landscape and emerging targets.

Authors:  Daniel H Ahn; Kristen K Ciombor; Sameh Mikhail; Tanios Bekaii-Saab
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

Review 3.  Growth factor signalling in endocrine and anti-growth factor resistant breast cancer.

Authors:  R I Nicholson; I R Hutcheson; H E Jones; S E Hiscox; M Giles; K M Taylor; J M W Gee
Journal:  Rev Endocr Metab Disord       Date:  2007-09       Impact factor: 6.514

Review 4.  Targeting insulin-like growth factor type 1 receptor in cancer therapy.

Authors:  Francesco Atzori; Tiffany A Traina; Maria Teresa Ionta; Bruno Massidda
Journal:  Target Oncol       Date:  2009-10-30       Impact factor: 4.493

5.  Constitutively active Harvey Ras confers resistance to epidermal growth factor receptor-targeted therapy with cetuximab and gefitinib.

Authors:  Rodney B Luwor; Yang Lu; Xinqun Li; Ke Liang; Zhen Fan
Journal:  Cancer Lett       Date:  2011-03-15       Impact factor: 8.679

6.  Combination of anti-IGF-1R antibody A12 and ionizing radiation in upper respiratory tract cancers.

Authors:  Oliver Riesterer; Qiuan Yang; Uma Raju; Mylin Torres; David Molkentine; Nalini Patel; David Valdecanas; Luka Milas; K Kian Ang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-12-02       Impact factor: 7.038

7.  Fibroblast growth factor-10 prevents H2O2-induced cell cycle arrest by regulation of G1 cyclins and cyclin dependent kinases.

Authors:  D Upadhyay; W Chang; K Wei; M Gao; G D Rosen
Journal:  FEBS Lett       Date:  2006-12-18       Impact factor: 4.124

8.  Combating resistance to anti-IGFR antibody by targeting the integrin β3-Src pathway.

Authors:  Dong Hoon Shin; Hyo-Jong Lee; Hye-Young Min; Sun Phil Choi; Mi-Sook Lee; Jung Weon Lee; Faye M Johnson; Kapil Mehta; Scott M Lippman; Bonnie S Glisson; Ho-Young Lee
Journal:  J Natl Cancer Inst       Date:  2013-10-03       Impact factor: 13.506

9.  IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer.

Authors:  Gerrit Peters; Silvia Gongoll; Cord Langner; Michael Mengel; Pompiliu Piso; Jürgen Klempnauer; Josef Rüschoff; Hans Kreipe; Reinhard von Wasielewski
Journal:  Virchows Arch       Date:  2003-07-05       Impact factor: 4.064

Review 10.  Resistance mechanisms of tumour cells to EGFR inhibitors.

Authors:  F Morgillo; F Cantile; M Fasano; T Troiani; E Martinelli; F Ciardiello
Journal:  Clin Transl Oncol       Date:  2009-05       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.